In our own previous work, we have developed the triazolyl NTSR1 antagonist FAUC468 [28] (Figure 1), demonstrating excellent tumor growth inhibition with 177Lu-FAUC468 (Ki (NTSR1) = 0.22 nM) in animal models of prostate PC3 tumor-bearing and pancreatic AsPC-1 tumor-bearing mice after the administration of single and double doses of 20–30 MBq/animal, respectively, without any detectable signs of tissue damage in the liver or kidneys [28]. This evidence concerns the gene NTSR1 and neoplasm.